Receptor-dependent formation of endogenous cannabinoids in cortical neurons

https://doi.org/10.1016/S0014-2999(01)01182-7Get rights and content

Abstract

We investigated the transduction mechanisms mediating formation of the endogenous cannabinoid (endocannabinoid) lipids, anandamide (arachidonylethanolamide) and 2-arachidonylglycerol, in primary cultures of rat cortical neurons. Unstimulated neurons contained 0.3±0.1 pmol of anandamide and 16.5±3.3 pmol of 2-arachidonylglycerol per mg of protein, as determined by gas chromatography/mass spectrometry. Ca2+ entry into the neurons via activated glutamate N-methyl-d-aspartate (NMDA) receptors increased 2-arachidonylglycerol levels approximately three times, but had no effect on anandamide levels. By contrast, anandamide formation was stimulated five times by simultaneous activation of NMDA and acetylcholine receptors. Alone, acetylcholine receptor activation had no effect on anandamide or 2-arachidonylglycerol levels. The formation of fatty acid ethanolamides that do not activate cannabinoid receptors, including palmitylethanolamide and oleylethanolamide, was stimulated by coactivation of NMDA and acetylcholine receptors. Pharmacological experiments suggest that the cholinergic contribution to anandamide formation was mediated by α7 nicotinic receptors (antagonized by methyllycaconitine), whereas the contribution to palmitylethanolamide and oleylethanolamide formation was mediated by muscarinic receptors (antagonized by atropine). These findings indicate that cortical neurons produce anandamide and 2-arachidonylglycerol in a receptor-dependent manner, and that brain neurons may generate different endocannabinoid lipids depending on their complement of neurotransmitter receptors.

Introduction

Cannabinoid receptors, the molecular target for the psychoactive constituent of Cannabis Δ9-tetrahydrocannabinol (Piomelli et al., 2000), are activated by a family of lipid molecules that primarily include anandamide (arachidonylethanolamide) Devane et al., 1992, Di Marzo et al., 1994 and 2-arachidonylglycerol Mechoulam et al., 1995, Sugiura et al., 1995, Stella et al., 1997. Both anandamide and 2-arachidonylglycerol are produced by brain neurons in an activity-dependent manner Di Marzo et al., 1994, Stella et al., 1997, Giuffrida et al., 1999, bind to and activate cannabinoid CB1 receptors Felder et al., 1993, Vogel et al., 1993, Mechoulam et al., 1995, Sugiura et al., 1996, and undergo rapid biological inactivation Di Marzo et al., 1994, Beltramo et al., 1997, suggesting that they may act as endogenous modulatory substances (Piomelli et al., 2000).

Unlike classical neurotransmitters, the endogenous cannabinoids (endocannabinoids) may be produced upon demand by enzymatic cleavage of membrane lipid precursors and immediately extruded from neurons without an intermediate step of vesicle storage Piomelli et al., 2000, Schmid, 2000. This feature—unusual in a brain chemical transmitter, but reminiscent of other lipid-derived mediators—prompted the two questions addressed in the present study. The first is how formation of anandamide and 2-arachidonylglycerol is initiated: is it stimulated by action potentials invading the synaptic nerve endings or by receptor-activated mechanisms? Previous studies have shown that anandamide and 2-arachidonylglycerol can be produced during neural activity in vitro and in vivo, but they have not investigated the cellular mechanisms of this response Di Marzo et al., 1994, Stella et al., 1997, Giuffrida et al., 1999. The second question is whether, regardless of the mechanism involved, anandamide and 2-arachidonylglycerol can be generated independently of each other. An affirmative answer to this question would imply that these compounds may be released under different circumstances and, possibly, serve distinct functional roles in neuronal signaling. To begin to address these questions, we have investigated the mechanisms of anandamide and 2-arachidonylglycerol formation in primary cultures of rat brain cortical neurons. The results of our experiments show that anandamide and 2-arachidonylglycerol are produced in a receptor-dependent manner, and that segregated molecular mechanisms may underlie the formation of each of these compounds.

Section snippets

Drugs

All drugs were purchased from Research Biochemical (Natick, MA) or Sigma (Saint Louis, MO).

Cell cultures

Cortical neurons were prepared as described Brewer, 1995, Evans et al., 1998, with few modifications. Cerebral cortices were dissected from 18-day-old Wistar rat embryos and the neurons were dissociated mechanically. The neurons (106 cells/ml) were then plated on 90-mm Corning® culture dishes (12.5 ml/dish) coated with poly-(l)-ornithine (10 μg/ml; molecular weight: 30,000–70,000) and poly-(dl)-lysine

Anandamide formation via coactivation of N-methyl-d-aspartate (NMDA) and acetylcholine receptors

We used isotope dilution gas chromatography/mass spectrometry to investigate anandamide biosynthesis in rat cortical neurons in primary culture (Giuffrida and Piomelli, 1998). Fig. 1A shows the ion current trace obtained after analysis of a lipid fraction purified from these cells. A diagnostic component of mass-to-charge ratio (m/z) 404 (the fragment produced from the molecular ion by loss of one methyl group), eluted from the column at the retention time of authentic standard, confirming that

Discussion

Despite their similar chemical structures, anandamide and 2-arachidonylglycerol are produced through distinct biochemical pathways. Formation of anandamide may result from hydrolysis of the phospholipid precursor N-arachidonyl phosphatidylethanolamine, catalyzed by a phosphodiesterase such as phospholipase D Di Marzo et al., 1994, Cadas et al., 1997, Schmid, 2000. 2-Arachidonylglycerol, on the other hand, may be produced by cleavage of 1,2-diacylglycerol generated by phospholipase C acting on

Acknowledgements

We thank Drs. Andrea Giuffrida, Felice Nava and Fernando Rodrı́guez de Fonseca for their critical reading of the manuscript, Mr. Fernando Valiño for editorial assistance, and Dr. John Bradly for his help with the veratridine calcium imaging experiments. Support from the National Institute of Drug Abuse (under grant number 12447, to D.P.) and the Tourette Syndrome Association is gratefully acknowledged.

References (40)

  • D. Piomelli et al.

    The endocannabinoid system as a target for therapeutic drugs

    Trends Pharmacol. Sci.

    (2000)
  • H.H. Schmid

    Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively?

    Chem. Phys. Lipids

    (2000)
  • T. Sugiura et al.

    2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

    Biochem. Biophys. Res. Commun.

    (1995)
  • T. Sugiura et al.

    2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma×glioma hybrid NG108-15 cells

    Biochem. Biophys. Res. Commun.

    (1996)
  • M. Alkondon et al.

    Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist

    Mol. Pharmacol.

    (1992)
  • M. Beltramo et al.

    Functional role of high-affinity anandamide transport, as revealed by selective inhibition

    Science

    (1997)
  • T. Bisogno et al.

    Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells

    Biochem. J.

    (1997)
  • G.J. Brewer

    Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus

    J. Neurosci. Res.

    (1995)
  • H. Cadas et al.

    Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP

    J. Neurosci.

    (1996)
  • H. Cadas et al.

    Occurrence and biosynthesis of endogenous cannabinoid precursor. N-arachidonoyl phosphatidylethanolamine, in rat brain

    J. Neurosci.

    (1997)
  • Cited by (201)

    • Cannabinoids

      2022, Advances in Neurotoxicology
    View all citing articles on Scopus
    1

    Present address: Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA.

    View full text